Catherine L Shuler

1.6k total citations · 1 hit paper
22 papers, 957 citations indexed

About

Catherine L Shuler is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Catherine L Shuler has authored 22 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Rheumatology, 18 papers in Immunology and 6 papers in Hematology. Recurrent topics in Catherine L Shuler's work include Psoriasis: Treatment and Pathogenesis (17 papers), Spondyloarthritis Studies and Treatments (16 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Catherine L Shuler is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (17 papers), Spondyloarthritis Studies and Treatments (16 papers) and Rheumatoid Arthritis Research and Therapies (12 papers). Catherine L Shuler collaborates with scholars based in United States, Japan and Canada. Catherine L Shuler's co-authors include Philip J. Mease, Désirée van der Heijde, Chen‐Yen Lin, Masato Okada, Chin H. Lee, Christopher T. Ritchlin, Raquel Cuchacovich, Dafna Gladman, Daniel Braun and Gary D. Grossfeld and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of Investigative Dermatology and Journal of the American Academy of Dermatology.

In The Last Decade

Catherine L Shuler

21 papers receiving 937 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Catherine L Shuler

Since Specialization

Citations

This map shows the geographic impact of Catherine L Shuler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine L Shuler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine L Shuler more than expected).

Fields of papers citing papers by Catherine L Shuler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine L Shuler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine L Shuler. The network helps show where Catherine L Shuler may publish in the future.

Co-authorship network of co-authors of Catherine L Shuler

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine L Shuler. A scholar is included among the top collaborators of Catherine L Shuler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine L Shuler. Catherine L Shuler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1) 2020 ·Lara D. Veeken ·Vinod Chandran, Désirée van der Heijde, Roy Fleischmann, Éric Lespessailles, Philip Helliwell, Hideto Kameda, Rubén Burgos‐Vargas, J. Erickson, Suchitrita S. Rathmann, (unknown), Julie Birt, Catherine L Shuler, Gaia Gallo	38
2	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies 2019 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Alice B. Gottlieb, Akimichi Morita, Joseph F. Merola, Chen‐Yen Lin, Julie Birt, Catherine L Shuler, Matthew M. Hufford, Diamant Thaçi	37
3	Ixekizumab Provides Sustained Improvement In Signs And Symptoms In Patients With Active Psoriatic Arthritis: Two Year Results From A Phase 3 Trial 2018 ·White Rose Research Online (University of Leeds, The University of Sheffield, University of York) ·P Helliwell, Éric Lespessailles, Catherine L Shuler, Lotus Mallbris, J. Erickson, Roy Fleischmann, D. Gladman	1
4	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity 2018 ·BMC Rheumatology ·Laura C. Coates, Ana‐Maria Orbai, Akimichi Morita, Olivier Bénichou, Lisa Kerr, David H. Adams, Catherine L Shuler, Julie Birt, Philip Helliwell	25
5	Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis 2018 ·Journal of the American Academy of Dermatology ·Alice B. Gottlieb, Kim Papp, C. Birbara, Catherine L Shuler, Russel Burge, J. Erickson, Lisa Kerr, Philip J. Mease	5
6	397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis 2017 ·Journal of Investigative Dermatology ·Philip J. Mease, Masato Okada, Mitsumasa Kishimoto, Catherine L Shuler, Hilde Carlier, Chen‐Yen Lin, (unknown), (unknown), (unknown), Dafna D. Gladman, (unknown)	7
7	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1) 2017 ·The Journal of Rheumatology ·Désirée van der Heijde, Dafna D. Gladman, Mitsumasa Kishimoto, Masato Okada, Suchitrita S. Rathmann, (unknown), Catherine L Shuler, Hilde Carlier, Olivier Bénichou, Philip J. Mease	96
8	Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks 2017 ·SKIN The Journal of Cutaneous Medicine ·Désirée van der Heijde, Masato Okada, Chin Lee, Catherine L Shuler, Suchitrita S. Rathmann, Chen‐Yen Lin, Philip J. Mease	2
9	Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1 2017 ·RMD Open ·Laura C. Coates, Mitsumasa Kishimoto, Alice B. Gottlieb, Catherine L Shuler, Chen‐Yen Lin, (unknown), Philip J. Mease	24
10	Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER‐A) 2016 ·Journal of the European Academy of Dermatology and Venereology ·Kristina Callis Duffin, Jerry Bagel, Michael Bukhalo, I Clement', (unknown), Fangyi Zhao, Anne Gill, Beth A. Pangallo, Catherine L Shuler, Lotus Mallbris, Kimberley Jackson	35
11	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 breakdown → 2016 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, Masato Okada, Raquel Cuchacovich, Catherine L Shuler, Chen‐Yen Lin, Daniel Braun, Chin H. Lee, Dafna Gladman	431
12	The efficacy and safety of ixekizumab, adalimumab, and placebo in patients with psoriatic arthritis naive to biological disease-modifying anti-rheumatic drugs : a double-blind phase 3 study 2016 ·Scandinavian Journal of Rheumatology ·Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, Raquel Cuchacovich, Catherine L Shuler, (unknown), (unknown), (unknown), (unknown), Dafna D. Gladman, E Larsson	0
13	A Randomized, Double-blind, Active-and Placebo-controlled Phase 3 Study of Efficacy and Safety of Ixekizumab, Adalimumab, and Placebo Therapy in Patients Naive to Biologic Disease Modifying Antirheumatic Drugs with Active Psoriatic Arthritis 2016 ·Experimental Dermatology ·(unknown), (unknown), Christopher T. Ritchlin, Raquel Cuchacovich, Catherine L Shuler, Chia‐Chi Lin, (unknown), (unknown), (unknown), Dafna D. Gladman	12
14	Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience 2016 ·Medical Devices Evidence and Research ·Kristina Callis Duffin, Michael Bukhalo, (unknown), David Shrom, Fangyi Zhao, (unknown), Anne Gill, Beth A. Pangallo, Catherine L Shuler, Jerry Bagel	17
15	THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis 2016 ·Annals of the Rheumatic Diseases ·Laura C. Coates, M. Elaine Husni, Catherine L Shuler, Hilde Carlier, Cai Lin, (unknown), (unknown), Philip J. Mease	5
16	OP0109 Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from A Phase 3 Study (Spirit-P1) 2016 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Masato Okada, Mitsumasa Kishimoto, Catherine L Shuler, Hilde Carlier, Chen‐Yen Lin, (unknown), (unknown), (unknown), Dafna Gladman	3
17	THU0441 Effect of Concomitant Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) on The Efficacy and Safety of Ixekizumab in Biologic Dmard-Naive Patients with Active Psoriatic Arthritis 2016 ·Annals of the Rheumatic Diseases ·Laura C. Coates, Alice B. Gottlieb, Catherine L Shuler, Chen‐Yen Lin, (unknown), (unknown), (unknown), Philip J. Mease	2
18	Treatment Patterns and Health Care Costs for Patients With Psoriatic Arthritis on Biologic Therapy: A Retrospective Cohort Study 2013 ·Clinical Therapeutics ·Baojin Zhu, Emily Edson‐Heredia, Jennifer Gatz, Jiaying Guo, Catherine L Shuler	26
19	Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease 2012 ·International Psychogeriatrics ·Paula T. Trzepacz, Jeffrey L. Cummings, (unknown), Tammy Forrester, (unknown), Ellen B. Dennehy, Brian A. Willis, Catherine L Shuler, Linda B. Tabas, Constantine G. Lyketsos	43
20	Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. 2001 ·PubMed ·Gary D. Grossfeld, J. Stuart Wolf, Mark S. Litwin, Hedvig Hricak, Catherine L Shuler, David C. Agerter, Peter R. Carroll	120

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact